Trade ALNY stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Alnylam Pharmaceuticals, Inc. (ALNY) is trading at US$223.82, down 1.41% today as of Oct 13, 16:00 EDT. The company has a market capitalisation of US$31.61B. Over the past 52 weeks, ALNY has traded between US$197.81 and US$495.55. On Syfe you can trade ALNY with $0 commission and add it to your watchlist.
| Previous close | US$227.02 |
|---|---|
| Market cap | US$31.61B |
| P/E ratio | 24.07 |
| 52-week range | US$197.81 – US$495.55 |
| Volume | 1.06M |
| Exchange | US |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.
Year: 2004
Alnylam's Zilebesiran Sees Commercial Opportunity From Baxfendy Launch, Oppenheimer Says
Sep 4, 3:15 PM · MT Newswires
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Aug 31, 3:40 PM · MT Newswires
Alnylam Pharmaceuticals Share Price Weakness Looks 'Overdone' Despite Softer Quarter, RBC Says
Jul 31, 3:03 PM · MT Newswires
Alnylam Pharmaceuticals, Inc. (ALNY) stock is trading at US$223.82, -1.41% from the previous close of US$227.02.
The market cap for Alnylam Pharmaceuticals, Inc. (ALNY) stock is approximately US$31.61B.
The price-to-earnings ratio for Alnylam Pharmaceuticals, Inc. (ALNY) is 24.07, based on the latest reported earnings.
The 52-week high for Alnylam Pharmaceuticals, Inc. (ALNY) stock is US$495.55.
The 52-week low for Alnylam Pharmaceuticals, Inc. (ALNY) stock is US$197.81.
Alnylam Pharmaceuticals, Inc. (ALNY) does not currently pay a dividend.
Stay on top of ALNY
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
